New research data surrounding this compound, specifically the high-dose formulation branded as ZPHC, reveal a considerable effect on body mass reduction and linked chronic conditions . Experts posit that this innovative agonist , targeting both GLP-1 and GIP pathways , could offer a major advance in the approach of obesity and related health probl